Concourse Financial Group Securities, Inc. Chemo Centryx, Inc. Transaction History

Concourse Financial Group Securities, Inc.

$1.64 Billion
Q3 2024

17 transactions

Quarter	Operation	Price Per share
Q3 2022 Nov 15, 2022	BUY	$22.17 - $51.8 $0 - $0
Q2 2022 Aug 09, 2022	BUY	$15.36 - $27.51 $0 - $0
Q1 2022 May 09, 2022	BUY	$22.22 - $39.12 $0 - $0
Q4 2021 Feb 07, 2022	BUY	$18.38 - $40.5 $0 - $0
Q3 2021 Nov 09, 2021	BUY	$13.18 - $19.83 $0 - $0
Q2 2021 Aug 13, 2021	BUY	$9.59 - $50.88 $0 - $0
Q1 2021 May 13, 2021	BUY	$49.53 - $68.4 $0 - $0
Q4 2020 Feb 02, 2021	BUY	$47.25 - $65.16 $0 - $0
Q3 2020 Nov 13, 2020	BUY	$46.35 - $61.69 $0 - $0
Q2 2020 Aug 13, 2020	BUY	$38.58 - $65.07 $0 - $0
Q1 2020 May 13, 2020	BUY	$32.73 - $50.78 $0 - $0
Q4 2019 Feb 14, 2020	BUY	$6.81 - $39.55 $0 - $0
Q3 2019 Nov 13, 2019	BUY	$6.47 - $8.96 $0 - $0
Q2 2019 Aug 13, 2019	BUY	$8.31 - $14.85 $0 - $0
Q1 2019 May 15, 2019	BUY	$10.01 - $13.89 $0 - $0
Q4 2018 Feb 14, 2019	BUY	$9.15 - $12.26 $0 - $0
Q3 2018 Nov 13, 2018	BUY	$10.49 - $13.72 $0 - $0

Others Institutions Holding CCXI

# of Institutions

Shares Held

66.3K

Call Options Held

Put Options Held

View Full List

About ChemoCentryx, Inc.

Ticker CCXI
Exchange NASDAQ
Shares Outstandng 71,919,696
Market Cap $3.68M
Description
ChemoCentryx, Inc., a biopharmaceutical company, focuses on the development and commercialization of new medications for inflammatory disorders, autoimmune diseases, and cancer in the United States. It offers TAVNEOS (avacopan), an orally administered selective C5aR inhibitor for the treatment of adult patients with severe active anti-neutrophil...

More about CCXI

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Concourse Financial Group Securities, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Concourse Financial Group Securities, Inc. with notifications on news.

Account